西格列汀聯(lián)合二甲雙肌標準化治療2型糖尿病患者早期大血管病變效果
打開文本圖片集
Standardized Treatment of Sitagliptin and Metformin in Early Macroangiopathy in Patients with Type 2 Diabetes
LIU Xiaoping XUE Shirong* （Liangzhou Hospital，WuweiCity，GansuProvince）
Abstract： Objective：To investigatethe efectof sitagliptin combined with metformin in the treatment of early macroangiopathy in patients with type 2 diabetes.Methods： A total of 80 patients with early type2 diabetes with macrovasculardisease admited toLiangzhou Hospital，Wuwei CityGansuProvince fromJanuary 2O23to December 2023 were randomly divided into the control group and the study group， with 40 cases in each group.The control group received metformin standardized treatment，and the study group received sitagliptin combined with metformin standardized treatment.Bloodglucose indexes，serumcystatin C，homocysteine，C-reactive protein，andthe incidence of adversereactions were compared between the two groups.Results：Thefastingblood glucose，2h postprandial blood glucose and HBAlc values of the study group were significantly lower than those of the control group （P<0.05） . After treatment，the levels of cystatin C，homocysteine and C-reactive protein in the study group were significantly lower than those in the control group （P<0.05） .There was no significant difference in the incidence of adverse reactions between groups （P>0.05） .Conclusion： Sitagliptin combined with metformin is effective in the treatment of early macroangiopathy in patientswith type2diabetes.
Keywords： type 2 diabetes; macroangiopathy; sitagliptin; metformin; standardized treatment
0 引言
2型糖尿病是發(fā)病率很高的慢性疾病，病程長、無法治愈，確診后需要終身治療，以控制血糖，保持穩(wěn)定"。（剩余3381字）